Skip to Main Content

Paper Details

Safety and antiviral activity of triple combination broadly neutralizing monoclonal antibody therapy against HIV-1: a phase 1 clinical trial.
Nature Medicine
30
2022
CD4, CD4 T cell, HIV, HIV-, HIV-1, HIV-1 V2-glycan-specific antibody, HIV-1 sequence variations, PGDM1400, PGT121, V3-glycan-specific antibody PGT121, VRC07, VRC07-523LS, human, participants, plasma HIV RNA, viremia, viremic
Author NameAffiliation
Elena E GiorgiLos Alamos National Laboratory
Elena E Giorgi
John R MascolaVaccine Research Center, National Institute of Health
Edwin DeJesus
Michael S SeamanCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center
Bette KorberLos Alamos National Laboratory
Bette Korber
Dan H BarouchRagon Institute of MGH
Dan H BarouchCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center
  • 1 - 9

Datasets

Release 1.2